The compound EC5026, also known as BPN-19186, is a potent, orally bioavailable inhibitor of soluble epoxide hydrolase (sEH). This enzyme plays a crucial role in the metabolism of fatty acid epoxides, which are involved in various physiological processes, including inflammation and pain modulation. Pain Management: EC5026 has been investigated for its efficacy in treating various pain conditions, including those in veterinary settings, including in dogs, cats, and horses. Neurological Research: The compound is being explored for its potential in treating neurological disorders like Parkinson’s disease and dementia with Lewy bodies. The directory classifies it as a clinical API with a synthetic source/manufacturing origin. Other names for this substance include D5X8A5HWL0, BPN-19186, UNII-D5X8A5HWL0 and CHEMBL4752759. Its PubChem CID is 91933845.
Ec-5026
| CAS No | 1809885-32-2 |
|---|---|
| Molecular Formula | C18H23F4N3O3 |
| Molecular Weight | 405.4 g/mol |
| Synonyms | 1-[3-fluoro-4-(trifluoromethoxy)phenyl]-3-[1-[(2S)-2-methylbutanoyl]piperidin-4-yl]urea |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
The compound EC5026, also known as BPN-19186, is a potent, orally bioavailable inhibitor of soluble epoxide hydrolase (sEH). This enzyme plays a crucial role in the metabolism of fatty acid epoxides, which are involved in various physiological processes, including inflammation and pain modulation.
The listed CAS number is 1809885-32-2.
The listed molecular formula is C18H23F4N3O3.
The listed molecular weight is 405.4 g/mol.
1-[3-fluoro-4-(trifluoromethoxy)phenyl]-3-[1-[(2S)-2-methylbutanoyl]piperidin-4-yl]urea.
The source lists D5X8A5HWL0, BPN-19186, UNII-D5X8A5HWL0 and CHEMBL4752759.